This small-cap healthcare stock engaged in providing diagnostic services across India, operating a central lab in Mumbai and a vast network of centers for reliable testing solutions, jumped to nearly its 20 percent upper limit after the company announced Q4 results and declared a final dividend of Rs. 21 per share.
Stock Price Movements
With a market capitalization of Rs. 4,698.66 crores, the share of Thyrocare Technologies Limited has reached an intraday high of Rs. 921 per equity share, rising nearly 19.79 percent from its previous day’s close price of Rs. 768.85. Since then, the stock has retreated and is currently trading at Rs. 886.65 per equity share.
Q4 FY25 Result Walkthrough
Coming into the quarterly results of Thyrocare Technologies Limited, the company’s consolidated revenue from operations increased by 21.34 percent YOY, from Rs. 154.25 crore in Q4 FY24 to Rs. 187.16 crore in Q4 FY25, and grew by 12.80 percent QoQ from Rs. 165.92 crore in Q3 FY25. Further, the company’s EBITDA has increased by 69.82 percent, from Rs. 33.8 crore in Q4 FY24 to Rs. 57.4 crore in Q4 FY25.
In Q4 FY25, Thyrocare Technologies Limited’s consolidated net profit increased by 25.55 percent YOY, reaching Rs. 21.57 crore compared to Rs. 17.18 crore during the same period last year. As compared to Q4 FY25, the net profit has increased by 13.83 percent, from Rs. 18.95 crore in Q3 FY25.
The basic earnings per share increased by 17.80 percent and stood at Rs. 4.17 as against Rs. 3.54 recorded in the same quarter in the previous year 2024.
Also read: Power Demand Surge: How IEX Stands to Benefit This Summer?
Dividend
The Thyrocare Technologies board of directors has recommended paying a final dividend at the rate of 210% on the face value of paid-up equity shares of Rs. 10 each for the financial year 2024-25, which is a dividend of Rs. 21 per equity share. The payment shall be made within 30 days from the date of the Annual General Meeting (AGM).
Financial Highlights (FY24-25)
Thyrocare Technologies Limited’s revenue has increased from Rs. 571.88 crore in FY24 to Rs. 687.35 crore in FY25, which is a growth of 20.19 percent. The net profit has also grown by 30.59 percent, from Rs. 69.49 crore in FY24 to Rs. 90.75 crore in FY25.
Geographical Presence
The company operates a central processing laboratory in Mumbai, supported by 20 regional labs, 3 zonal labs, and 5 satellite labs spread across India. It is continuously growing and has expanded its presence to over 7,400 centers in more than 570 districts across the country.
Company Overview
Thyrocare Technologies Limited is a leading diagnostic services provider in India, specializing in clinical laboratory testing. The company operates a central lab in Mumbai and a vast network of centers across the country, offering cost-effective and reliable diagnostic solutions.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
